KZA.AX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (13 Nov 2023 @ 13:10):

Stats
今日成交量	454 181
平均成交量	473 092
市值	18.91M
EPS	$0 ( 2024-02-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.727
ATR14	$0.00800 (10.00%)

音量相关性

長: -0.67 (moderate negative)

短: 0.15 (neutral)

Signal:(43.949) Neutral

Kazia Therapeutics Ltd 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kazia Therapeutics Ltd 相关性 - 货币/商品

-0.12
( neutral )

-0.59
( weak negative )

0.00
( neutral )

-0.06
( neutral )

0.73
( moderate )

0.66
( moderate )

Kazia Therapeutics Ltd 财务报表

Annual	2022
营收:	$555.00
毛利润:	$555.00 (100.00 %)
EPS:	$-0.110

FY	2022
营收:	$555.00
毛利润:	$555.00 (100.00 %)
EPS:	$-0.110

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.190

FY	2021
营收:	$15.18M
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0716

Financial Reports:

No articles found.

Kazia Therapeutics Ltd

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.